Another Smo inhibitor—NVP-LDE225 (erismodegib)—has been shown to restore vascular density in pancreatic ductal adenocarcinoma, to decrease pericyte coverage and to enhance vessel permeability, suggesting an increased proportion of immature microvessels [102]. This evidence concerns the gene SMO and pancreatic ductal adenocarcinoma.